The short version
8 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Amlodipine and Olmesartan Medoxomil
Amlodipine and Olmesartan Medoxomil · AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 · Tablet, Film Coated · Oral · AvKARE
NDC 42291-0002-30 · 30 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 68462-0568-30) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$0.5591per unit
middle half $0.2017–$1.11 · 5,511 plans · Jan 1, 2024
Est. net of rebatesⓘ
≈ $0.5591
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
—of plans cover it
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 1 quarter since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$263.60
Reported to Texas DSHS · 2026 annual filing · AvKare
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.2%chance of a new FDA shortage posting for amlodipine and olmesartan medoxomil (oral solid) in the next 90 days
OAI inspection at a producing facility (24 months) · sole-source market · 2 Class I/II recall(s) in 12 months
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Regulatory
- Application
- ANDA209010
- TE code
- AB
- Approval date
- Dec 3, 2018
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Amlodipine and Olmesartan Medoxomil (Tablet, Film Coated)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| A-S Medication Solutions | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals NY LLC | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals NY LLC | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals NY LLC | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals NY LLC | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AvKARE | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Camber Pharmaceuticals, Inc. | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Glenmark Pharmaceuticals Inc., USA | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Macleods Pharmaceuticals Limited | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| ScieGen Pharmaceuticals, Inc | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| ScieGen Pharmaceuticals, Inc | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| ScieGen Pharmaceuticals, Inc | AMLODIPINE BESYLATE 5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| ScieGen Pharmaceuticals, Inc | AMLODIPINE BESYLATE 10 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Amlodipine and Olmesartan Medoxomil — NDC 42291-0002-30," retrieved September 3, 2026, https://drugdashboards.com/drug/42291000230.
Free to cite with attribution — see how the data is put together.